Table 6.
Arterial hypertension | |
Imatinib | p = 0.743 |
Dasatinib | p = 0.732 |
Nilotinib | p = 0.305 |
Imatinib/dasatinib vs. nilotinib | p = 0.105 |
White coat hypertension | |
Imatinib | p = 0.973 |
Dasatinib | p = 0.073 |
Nilotinib | p = 0.940 |
Imatinib/dasatinib vs. nilotinib | p = 1 |
Masked hypertension | |
Imatinib | p = 0.363 |
Dasatinib | p = 1 |
Nilotinib | p = 1 |
Imatinib/dasatinib vs. nilotinib | p = 1 |
Uncontrolled blood pressure | |
Imatinib | p = 0.738 |
Dasatinib | p = 0.564 |
Nilotinib | p = 0.094 |
Imatinib/dasatinib vs. nilotinib | p = 0.041 |
Values highlighted in bold underline statistically significant results.
Comparative analysis of hypertension, white coat hypertension, masked hypertension, and uncontrolled blood pressure with the groups of patients analyzed (imatinib, dasatinib, nilotinib, imatinib + dasatinib).